XILIO THERAPEUTICS
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The companyโs tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across can... cer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
XILIO THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2016-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.akriveiatx.com
Total Employee:
11+
Status:
Active
Contact:
(609)560-0927
Email Addresses:
[email protected]
Total Funding:
233 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Google Tag Manager Content Delivery Network Font Awesome Apache Global Site Tag
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
RiverVest
RiverVest investment in Series C - Xilio Therapeutics
Deerfield
Deerfield investment in Series C - Xilio Therapeutics
SV Health Investors
SV Health Investors investment in Series C - Xilio Therapeutics
Takeda Ventures
Takeda Ventures investment in Series C - Xilio Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Xilio Therapeutics
Atlas Venture
Atlas Venture investment in Series C - Xilio Therapeutics
MRL Ventures Fund
MRL Ventures Fund investment in Series C - Xilio Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series C - Xilio Therapeutics
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series C - Xilio Therapeutics
SV Health Investors
SV Health Investors investment in Series B - Xilio Therapeutics
Key Employee Changes
Date | New article |
---|---|
2021-10-12 | Xilio Therapeutics Appoints Timothy D. Hunt as Chief Culture and Corporate Affairs Officer |
2020-04-27 | Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer |
Official Site Inspections
http://www.akriveiatx.com
- Host name: 172.65.190.172
- IP address: 172.65.190.172
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago